Skip to content
Review Open access

A Review of Neuroproteomics in Neurological Disorders: The Use of Machine Learning and Deep Learning

Aug 2026 · The Scientist · Vol 8, pp. 207 · 0 citations · 110 references

TL;DR

This review summarizes current advances in proteomics across a range of brain disorders, highlighting key molecular pathways, biomarker discovery efforts, and evolving clinical applications and outlines future directions, including the application of machine learning for improved biomarker identification and precision medicine.

Abstract

Proteomics has emerged as a powerful tool for advancing our understanding of brain disorders by enabling large-scale characterization of protein expression, post-translational modifications, and interaction networks. Neurological conditions are often characterized by complex and dynamic molecular changes that are not fully captured by traditional diagnostic approaches. Proteomic technologies, particularly mass spectrometry-based and affinity-based methods, offer the ability to identify disease-specific protein signatures and elucidate underlying pathophysiological mechanisms, including neurodegeneration, neurodevelopment and neuroinflammation and alterations happening to the extracellular matrix and body fluid homeostasis. In recent years, artificial intelligence has emerged as a powerful tool to proteomics, enabling improved analysis of complex biological datasets. This integration has significantly enhanced the discovery of biomarkers for early diagnosis, disease stratification, and monitoring of therapeutic responses. Thus, cerebrospinal fluid and blood-based proteomic analyses have revealed promising candidates for neurological diseases. This review summarizes current advances in proteomics across a range of brain disorders, highlighting key molecular pathways, biomarker discovery efforts, and evolving clinical applications. Furthermore, it outlines future directions, including the application of machine learning for improved biomarker identification and precision medicine.

Read PDF

Similar papers

Review 2026

Silent clues in blood: Proteomic approach for Alzheimer's disease.

Current research focused on blood protein biomarkers may reveal key clues for fully understanding the etiology of AD, enabling earlier diagnosis and monitoring of its progression, thereby paving the way for research targeting a cure.

Adriele Rebeca Vieira da Silva, Renata Santos Vieira da Conceição, Carla Mariana da Silva Medeiros et al. · 0 citations
Open access Sep 2026

369. Proteomic Signatures of Health and Aging.

Abstract Text: Mass spectrometry-based proteomics has become a cornerstone technology in biological and biomedical research by enabling the comprehensive analysis of thousands of proteins, their modifications and interactions in a single experiment. Because proteins are the cellular workhorse, proteomics provides a p...

U. Aryal · 0 citations
Review Aug 2026

Neuropharmacology in the Era of Precision Medicine: From Synaptic Targets to Personalized Therapies.

Neuropsychiatric and neurodegenerative disorders show wide variability in treatment response, thus limiting the effectiveness of traditional symptom-based neuropharmacology. Precision medicine offers a more targeted approach by combining pharmacogenomics, multi-omics data, and artificial intelligence to guide individua...

L. Al-Eitan · 0 citations
Review Aug 2026

Exosome-derived biomarkers as non-invasive tools in stroke, Parkinson’s disease, and Alzheimer’s disease

This review focuses on exosome-derived proteins and small non-coding RNAs as promising non-invasive biomarkers for stroke, PD, and AD, given the accessibility and stability of exosomes in biological fluids, and examines their potential diagnostic and therapeutic relevance.

Athar Talebi, Samira Nabili, Mobarakeh Alaei et al. · 0 citations
Open access

A proteomic approach to unravel neurodegeneration

The potential of proteomics to characterize the molecular complexity of AD and reveal interconnected changes across different levels of disease biology is demonstrated, supporting a view of AD as a progressive disruption of cellular and intercellular communication and emphasizing the need for multi-targeted approaches...

Evangelia Thanou · 0 citations
Review Open access Aug 2026

Neurofilament Light Chain (NfL) in Neurodegenerative Diseases: Biological and Clinical Significance, Multi-Omics Integration, and AI-Driven Biomarker Modeling for Precision Therapy

Neurodegenerative diseases represent a major cause of disability and death, but early diagnosis, prognosis, and therapeutic monitoring are challenging due to biological heterogeneity and the absence of disease-specific biomarkers. Neurofilament light chain (NfL) is a highly sensitive fluid biomarker of neuroaxonal inju...

Nawaf Alshammari, Reyaz Hassan, Mitesh Patel et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.